Literature DB >> 8743085

Prediction of HIV peptide epitopes by a novel algorithm.

C G Roberts1, G E Meister, B M Jesdale, J Lieberman, J A Berzofsky, A S De Groot.   

Abstract

Identification of promiscuous or multideterminant T cell epitopes is essential for HIV vaccine development, however, current methods for T cell epitope identification are both cost intensive and labor intensive. We have developed a computer-driven algorithm, named EpiMer, which searches protein amino acid sequences for putative MHC class I- and/or class II-restricted T cell epitopes. This algorithm identifies peptides that contain multiple MHC-binding motifs from protein sequences. To evaluate the predictive power of EpiMer, the amino acid sequences of the HIV-1 proteins nef, gp160, gag p55, and tat were searched for regions of MHC-binding motif clustering. We assessed the algorithm's predictive power by comparing the EpiMer-predicted peptide epitopes to T cell epitopes that have been published in the literature. The EpiMer method of T cell epitope identification was compared to the standard method of synthesizing short, overlapping peptides and testing them for immunogenicity (overlapping peptide method), and to an alternate algorithm that has been used to identify putative T cell epitopes from primary structure (AMPHI). For the four HIV-1 proteins analyzed, the in vitro testing of EpiMer peptides for immunogenicity would have required the synthesis of fewer total peptides than either AMPHI or the overlapping peptide method. The EpiMer algorithm proved to be more efficient and more sensitive per amino acid than both the overlapping peptide method and AMPHI. The EpiMer predictions for these four HIV proteins are described. Since EpiMer-predicted peptides have the potential to bind to multiple MHC alleles, they are strong candidates for inclusion in a synthetic HIV vaccine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8743085     DOI: 10.1089/aid.1996.12.593

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  7 in total

1.  Immunogenic and protective potential of mutans streptococcal glucosyltransferase peptide constructs selected by major histocompatibility complex class II allele binding.

Authors:  S Culshaw; K Larosa; H Tolani; X Han; J W Eastcott; D J Smith; M A Taubman
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

2.  Immunogenicity and protective immunity induced by synthetic peptides associated with putative immunodominant regions of Streptococcus mutans glucan-binding protein B.

Authors:  Daniel J Smith; William F King; Leigh A Barnes; Zachary Peacock; Martin A Taubman
Journal:  Infect Immun       Date:  2003-03       Impact factor: 3.441

Review 3.  High throughput T epitope mapping and vaccine development.

Authors:  Giuseppina Li Pira; Federico Ivaldi; Paolo Moretti; Fabrizio Manca
Journal:  J Biomed Biotechnol       Date:  2010-06-15

4.  Identification of novel immunodominant CD4+ Th1-type T-cell peptide epitopes from herpes simplex virus glycoprotein D that confer protective immunity.

Authors:  Lbachir BenMohamed; Georges Bertrand; Cory D McNamara; Helene Gras-Masse; Juergen Hammer; Steven L Wechsler; Anthony B Nesburn
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

5.  Prediction of B-cell linear epitopes with a combination of support vector machine classification and amino acid propensity identification.

Authors:  Hsin-Wei Wang; Ya-Chi Lin; Tun-Wen Pai; Hao-Teng Chang
Journal:  J Biomed Biotechnol       Date:  2011-08-23

6.  A common minimal motif for the ligands of HLA-B*27 class I molecules.

Authors:  Alejandro Barriga; Elena Lorente; Carolina Johnstone; Carmen Mir; Margarita del Val; Daniel López
Journal:  PLoS One       Date:  2014-09-30       Impact factor: 3.240

Review 7.  T cell epitope: friend or foe? Immunogenicity of biologics in context.

Authors:  Constanze A Weber; Preema J Mehta; Matt Ardito; Lenny Moise; Bill Martin; Anne S De Groot
Journal:  Adv Drug Deliv Rev       Date:  2009-07-18       Impact factor: 15.470

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.